PatientsVille.com Logo

PatientsVille

Cymbalta Side Effects

Common Cymbalta Side Effects


The most commonly reported Cymbalta side effects (click to view or check a box to report):

Nausea (1362)
Dizziness (1252)
Headache (900)
Feeling Abnormal (847)
Fatigue (734)
Depression (731)
Insomnia (721)
Anxiety (624)
Alanine Aminotransferase Increased (619)
Paraesthesia (558)
Hyperhidrosis (557)
Diarrhoea (546)
Aspartate Aminotransferase Increased (536)
Suicidal Ideation (503)
Hepatic Enzyme Increased (466)
Blood Pressure Increased (463)
Vomiting (431)
Loss Of Consciousness (427)
Fall (422)
Asthenia (420)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Cymbalta Side Effects Reported to FDA

The following Cymbalta reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Cymbalta on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Dysphagia, Nausea, Dizziness, Hallucination, Paraesthesia, Muscle Spasms, Chills, Pain
This is a report of a 33-year-old female patient (weight: NA) from US, suffering from the following symptoms/conditions: neck pain,back pain, who was treated with Cymbalta (dosage: 1 Pill 1 Time Per Day, start time: NS), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:
  • Dysphagia
  • Nausea
  • Dizziness
  • Hallucination
  • Paraesthesia
  • Muscle Spasms
  • Chills
  • Pain
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Cymbalta treatment in female patients, resulting in dysphagia side effect.

Lethargy, Myalgia, Headache, Nausea, Vomiting
This report suggests a potential Cymbalta Lethargy, Myalgia, Headache, Nausea, Vomiting side effect(s) that can have serious consequences. A male patient (weight: NA) from US was diagnosed with the following symptoms/conditions: NA and used Cymbalta (dosage: 30 Mg, Bid) starting Oct 10, 2013. Soon after starting Cymbalta the patient began experiencing various side effects, including:
  • Lethargy
  • Myalgia
  • Headache
  • Nausea
  • Vomiting
Drugs used concurrently: NA.The patient was hospitalized. Although Cymbalta demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as lethargy, may still occur.

Halo Vision, Aura, Impaired Work Ability, Dry Mouth, Dry Eye, Gait Disturbance, Hypertension
This Halo Vision, Aura, Impaired Work Ability, Dry Mouth, Dry Eye, Gait Disturbance, Hypertension problem was reported by a consumer or non-health professional from US. A 64-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: neuropathy peripheral,depression. On Aug 01, 2009 this consumer started treatment with Cymbalta (dosage: 1 X Night). The following drugs were being taken at the same time: NA. When commencing Cymbalta, the patient experienced the following unwanted symptoms/side effects:
  • Halo Vision
  • Aura
  • Impaired Work Ability
  • Dry Mouth
  • Dry Eye
  • Gait Disturbance
  • Hypertension
Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as halo vision, may become evident only after a product is in use by the general population.

Asthma, Off Label Use
This is a report of a 40-year-old female patient (weight: NA) from GB. The patient developed the following symptoms/conditions: depression and was treated with Cymbalta (dosage: 60 Mg, Qd) starting NS. Concurrently used drugs: NA.Soon after that, the consumer experienced the following side effects:
  • Asthma
  • Off Label Use
The patient was hospitalized. This opens a possibility that Cymbalta treatment could cause the above reactions, including asthma, and some female subjects may be more susceptible.


Nightmare, Hypoaesthesia, Paraesthesia, Hyperhidrosis, Nausea, Feeling Cold, Pain
A 42-year-old female patient (weight: NA) from US with the following symptoms/conditions: NA started Cymbalta treatment (dosage: NA) on NS. Soon after starting Cymbalta treatment, the subject experienced various side effects, including:
  • Nightmare
  • Hypoaesthesia
  • Paraesthesia
  • Hyperhidrosis
  • Nausea
  • Feeling Cold
  • Pain
Concurrently used drugs: NA. This finding indicates that some female patients could be more vulnerable to Cymbalta.

Dysphemia, Paraesthesia, Nausea, Anxiety, Emotional Distress, Weight Increased
A 40-year-old male patient from US (weight: NA) experienced symptoms, such as: depression and was treated with Cymbalta(dosage: 1 Time Daily Once Daily Taken By Mouth). The treatment was initiated on NS. After that a consumer reported the following side effect(s):
  • Dysphemia
  • Paraesthesia
  • Nausea
  • Anxiety
  • Emotional Distress
  • Weight Increased
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Cymbalta efficacy: NA.

Deep Vein Thrombosis, Gallbladder Non-functioning, Depression, Pain, Memory Impairment
In this report, Cymbalta was administered for the following condition: pain,ankylosing spondylitis.A 29-year-old female consumer from US (weight: NA) started Cymbalta treatment (dosage: By Mouth) on Sep 23, 2013.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Deep Vein Thrombosis
  • Gallbladder Non-functioning
  • Depression
  • Pain
  • Memory Impairment
A possible interaction with other drugs could have contributed to this reaction: NA.The patient was hospitalized.Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Cymbalta treatment could be related to the listed above side effect(s).

Product Substitution Issue
This is a report of the following Cymbalta side effect(s):
  • Product Substitution Issue
A 50-year-old female patient from US (weight: NA) presented with the following condition: depression and received a treatment with Cymbalta (dosage: 30 Mg Daily Oral?approx 1-2 Months) starting: NS.The following concurrently used drugs could have generated interactions: NA.This report suggests that a Cymbalta treatment could be associated with the listed above side effect(s).

Contusion, Abdominal Pain
This Cymbalta report was submitted by a 53-year-old consumer from US (weight: NA). The patient was diagnosed with: NA and Cymbalta was administered (dosage: NA) starting: NS. The consumer developed a set of symptoms:
  • Contusion
  • Abdominal Pain
Other drugs used simultaneously: NA.Those unexpected symptoms could be linked to a Cymbalta treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Hyponatraemia, Pituitary Haemorrhage
This is a report of a possible correlation between Cymbalta use and the following symptoms/side effect(s):
  • Hyponatraemia
  • Pituitary Haemorrhage
which could contribute to an assessment of Cymbalta risk profile.A 70-year-old female consumer from JP (weight: NA) was suffering from depression,constipation and was treated with Cymbalta (dosage: 20 Mg, Bid) starting Dec 03, 2013.Other concurrent medications:
  • Magmitt (330 Mg, Tid)


Delirium, Hyponatraemia, Confusional State, Muscle Twitching, Somnolence, Off Label Use
A 71-year-old female patient from GB (weight: NA) presented with the following symptoms: neuralgia and after a treatment with Cymbalta (dosage: 30 Mg, Each Evening) experienced the following side effect(s):
  • Delirium
  • Hyponatraemia
  • Confusional State
  • Muscle Twitching
  • Somnolence
  • Off Label Use
The treatment was started on Feb 07, 2014. Cymbalta was used in combination with the following drugs:
  • Bendroflumethiazide (Unk)
  • Co-dydramol (Unk)
  • Durogesic (Unk)
  • Felodipine (Unk)
  • Irbesartan (Unk)
  • Levothyroxine (Unk)
  • Oramorph (Unk)
  • Pantoprazole (Unk)
The patient was hospitalized and became disabled.This report could alert potential Cymbalta consumers.

Hyponatraemia
In this report, a 76-year-old female patient from FR (weight: NA) was affected by a possible Cymbalta side effect.The patient was diagnosed with depression. After a treatment with Cymbalta (dosage: 60 Mg, Qd, start date: Dec 17, 2013), the patient experienced the following side effect(s):
  • Hyponatraemia
The following simultaneously used drugs could have led to this reaction:
  • Lyrica (150 Mg, Qd)
  • Rivotril (0.35 Ml (7 Drops), Qd)
  • Lipanthyl (160 Mg, Qd)
  • Amlor (5 Mg, Qd)
  • Debridat /00465201/ (Unk)
  • Doliprane (Unk)
The patient was hospitalized.The findings here stress that side effects should be taken into consideration when evaluating a Cymbalta treatment.

Stomatitis Necrotising, Sinusitis, Osteonecrosis, Tooth Loss, Mucosal Infection, Sinus Perforation, Cranial Nerve Disorder, Herpes Virus Infection, Oral Pain
This is a report of a 50-year-old female patient from US (weight: NA), who used Cymbalta (dosage: 30 Mg, Qd) for a treatment of depression,affective disorder,anxiety,attention deficit/hyperactivity disorder. After starting a treatment on 201112, the patient experienced the following side effect(s):
  • Stomatitis Necrotising
  • Sinusitis
  • Osteonecrosis
  • Tooth Loss
  • Mucosal Infection
  • Sinus Perforation
  • Cranial Nerve Disorder
  • Herpes Virus Infection
  • Oral Pain
The following drugs could possibly have interacted with the Cymbalta treatment NA.Taken together, these observations suggest that a Cymbalta treatment could be related to side effect(s), such as Stomatitis Necrotising, Sinusitis, Osteonecrosis, Tooth Loss, Mucosal Infection, Sinus Perforation, Cranial Nerve Disorder, Herpes Virus Infection, Oral Pain.

Pain, Hypertension, Dry Mouth
This pain side effect was reported by a consumer or non-health professional from MX. A 58-year-old female patient (weight:NA) experienced the following symptoms/conditions: arthritis. The patient was prescribed Cymbalta (dosage: NA), which was started on NS. Concurrently used drugs: NA. When starting to take Cymbalta the consumer reported the following symptoms:
  • Pain
  • Hypertension
  • Dry Mouth
The patient was hospitalized. These side effects may potentially be related to Cymbalta.

Hepatitis, Dyspnoea, Diarrhoea
This is a Cymbalta side effect report of a 66-year-old female patient (weight:NA) from US, suffering from the following symptoms/conditions: NA, who was treated with Cymbalta (dosage:60 Mg, Bid, start time: 2009), combined with: NA., and developed a serious reaction and a hepatitis side effect. The patient presented with:
  • Hepatitis
  • Dyspnoea
  • Diarrhoea
which developed after the beginning of treatment. This side effect report can indicate a possible existence of increased vulnerability to Cymbalta treatment in female patients suffering from NA, resulting in hepatitis.

Paresis, Dyspnoea, Myalgia, Blood Creatine Phosphokinase Increased, Gamma-glutamyltransferase Increased, Back Pain, Blood Alkaline Phosphatase Increased, Pain In Extremity, Hyperbilirubinaemia
This report suggests a potential Cymbalta paresis side effect(s) that can have serious consequences. A 70-year-old male patient from FR (weight:NA) was diagnosed with the following health condition(s): NA and used Cymbalta (dosage: 30 Mg, Qd) starting 2013. Soon after starting Cymbalta the patient began experiencing various side effects, including:
  • Paresis
  • Dyspnoea
  • Myalgia
  • Blood Creatine Phosphokinase Increased
  • Gamma-glutamyltransferase Increased
  • Back Pain
  • Blood Alkaline Phosphatase Increased
  • Pain In Extremity
  • Hyperbilirubinaemia
Drugs used concurrently:
  • Flecaine (30 Mg, Qd)
  • Prednisone (10 Mg, Each Morning)
  • Oxycontin (30 Mg, Bid)
  • Oxinorm /00045603/ (10 Mg, Until 4 Daily)
  • Flecaine (150 Mg, Qd)
  • Inexium /01479302/ (20 Mg, Each Morning)
  • Heptamyl (Unk, Tid)
  • Tardyferon (Unk, Each Morning)
The patient was hospitalized. Although Cymbalta demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as paresis, may still occur.

Stridor, Cough, Dysgeusia
This stridor problem was reported by a consumer or non-health professional from DE. A 47-year-old female patient (weight: NA) was diagnosed with the following medical condition(s): neuralgia.On 201311 a consumer started treatment with Cymbalta (dosage: 60 Mg, Qd). The following drugs/medications were being taken at the same time:
  • Pregabalin (150 Mg, Tid)
  • Amitriptylinoxide (60 Mg, Qd)
  • Tapentadol (100 Mg, Tid)
When commencing Cymbalta, the patient experienced the following unwanted symptoms /side effects:
  • Stridor
  • Cough
  • Dysgeusia
Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as stridor, may become evident only after a product is in use by the general population.

Completed Suicide
This is a Cymbalta side effect report of a 45-year-old female patient (weight: NA) from FR. The patient developed the following symptoms/conditions: NA and was treated with Cymbalta (dosage: NA) starting NS. Concurrently used drugs:
  • Zyprexa
Soon after that, the consumer experienced the following of symptoms:
  • Completed Suicide
This opens a possibility that Cymbalta could cause completed suicide and that some female patients may be more susceptible.

Skin Wrinkling, Eye Swelling, Dry Skin, Yellow Skin, Skin Discolouration
A 45-year-old female patient (weight: NA) from MX with the following symptoms: NA started Cymbalta treatment (dosage: 30 Mg, Qd) on Feb 13, 2014. Soon after starting Cymbalta treatment, the consumer experienced several side effects, including:
  • Skin Wrinkling
  • Eye Swelling
  • Dry Skin
  • Yellow Skin
  • Skin Discolouration
. Concurrently used drugs: NA. This finding indicates that some patients can be more vulnerable to developing Cymbalta side effects, such as skin wrinkling.

Dyspnoea, Tremor, Sleep Disorder, Mood Swings, Bipolar Disorder, Condition Aggravated
This dyspnoea side effect was reported by a health professional from US. A 48-year-old female patient (weight:NA) experienced the following symptoms/conditions: bipolar i disorder.The patient was prescribed Cymbalta (dosage: 30 Mg ( 3 Tabs) A Few Weeks Am Po), which was started on NS. Concurrently used drugs: NA..When starting to take Cymbalta the consumer reported symptoms, such as:
  • Dyspnoea
  • Tremor
  • Sleep Disorder
  • Mood Swings
  • Bipolar Disorder
  • Condition Aggravated
These side effects may potentially be related to Cymbalta.

Gingivitis, Periodontitis
This is a report of a 35-year-old female patient (weight: NA) from FR, suffering from the following symptoms/conditions: depression, who was treated with Cymbalta (dosage: NA, start time: Dec 16, 2013), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:
  • Gingivitis
  • Periodontitis
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Cymbalta treatment in female patients, resulting in gingivitis side effect.

Malnutrition, Protein Deficiency
This report suggests a potential Cymbalta Malnutrition, Protein Deficiency side effect(s) that can have serious consequences. A 46-year-old female patient (weight: NA) from US was diagnosed with the following symptoms/conditions: depression and used Cymbalta (dosage: 60 Mg, Tid) starting NS. Soon after starting Cymbalta the patient began experiencing various side effects, including:
  • Malnutrition
  • Protein Deficiency
Drugs used concurrently: NA.The patient was hospitalized. Although Cymbalta demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as malnutrition, may still occur.

Blood Alkaline Phosphatase Increased
This Blood Alkaline Phosphatase Increased problem was reported by a consumer or non-health professional from JP. A 48-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: depression. On NS this consumer started treatment with Cymbalta (dosage: 60 Mg, Qd). The following drugs were being taken at the same time: NA. When commencing Cymbalta, the patient experienced the following unwanted symptoms/side effects:
  • Blood Alkaline Phosphatase Increased
Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as blood alkaline phosphatase increased, may become evident only after a product is in use by the general population.

Blood Pressure Increased
This is a report of a 75-year-old male patient (weight: NA) from JP. The patient developed the following symptoms/conditions: depression and was treated with Cymbalta (dosage: 20 Mg, Qd) starting Mar 25, 2011. Concurrently used drugs:
  • Lyrica (Unk)
  • Voltaren /00372302/
  • Tramadol Hydrochloride And Acetaminophen
  • Nicorandil (10 Mg, Unk)
  • Artist (2.5 Mg, Unk)
  • Nexium /01479302/ (20 Mg, Unk)
  • Clopidogrel Sulfate (75 Mg, Unk)
  • Warfarin Potassium (1 Df, Unk)
Soon after that, the consumer experienced the following side effects:
  • Blood Pressure Increased
This opens a possibility that Cymbalta treatment could cause the above reactions, including death, and some male subjects may be more susceptible.

Cataract, Presyncope, Abdominal Pain Upper, Vomiting, Diarrhoea, Influenza
A 76-year-old female patient (weight: NA) from US with the following symptoms/conditions: depression started Cymbalta treatment (dosage: 60 Mg, Qd) on Feb 18, 2014. Soon after starting Cymbalta treatment, the subject experienced various side effects, including:
  • Cataract
  • Presyncope
  • Abdominal Pain Upper
  • Vomiting
  • Diarrhoea
  • Influenza
Concurrently used drugs: NA. This finding indicates that some female patients could be more vulnerable to Cymbalta.

1 of 575 



Top 10 Cymbalta Side Effects for Women

Women Side EffectsReports
Nausea 1106
Dizziness 988
Headache 738
Feeling Abnormal 685
Fatigue 587
Insomnia 556
Depression 535
Anxiety 466
Diarrhoea 466
Alanine Aminotransferase Increased 450

Top 10 Cymbalta Side Effects for Men

Men Side EffectsReports
Dizziness 253
Nausea 249
Depression 192
Alanine Aminotransferase Increased 168
Insomnia 163
Feeling Abnormal 160
Headache 158
Anxiety 155
Suicidal Ideation 150
Fatigue 145

Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Cymbalta Side Effects

    Did You Have a Cymbalta Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Cymbalta for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Cymbalta Safety Alerts, Active Ingredients, Usage Information

    NDC0002-3235
    TypeHUMAN PRESCRIPTION DRUG
    Proprietary NameCymbalta
    NameDuloxetine hydrochloride
    Dosage FormCAPSULE, DELAYED RELEASE
    RouteORAL
    On market since20040824
    LabelerEli Lilly and Company
    Active Ingredient(s)DULOXETINE HYDROCHLORIDE
    Strength(s)20
    Unit(s)mg/1
    Pharma ClassNorepinephrine Uptake Inhibitors [MoA],Serotonin and Norepinephrine Reuptake Inhibitor [EPC],Seroton

    Cymbalta Dosage, Warnings, Usage.

    Side Effects reported to FDA: 14373

    Cymbalta safety alerts: 2005

    Reported deaths: 928

    Reported hospitalizations: 4360

    Cymbalta (duloxetine) Public Health Advisory: Suicidality in Adults Being Treated with Antidepressant Medications

    Audience: Neuropsychiatric healthcare professionals and consumers

    [UPDATE 07/08/2005] FDA notified healthcare professionals about the availability of updated Healthcare Professional and Patient Information Sheets for antidepressant medications that were the subject of a June 30, 2005 Public Health Advisory issued about the risk of suicidality (suicidal thinking or behavior) in adults being treated with antidepressant medications.

    [Posted 07/01/2005] In response to recent scientific publications that report the possibility of increased risk of suicidal behavior in adults treated with antidepressants, the FDA has issued a Public Health Advisory to update patients and healthcare providers with the latest information on this subject. Even before the publication of these recent reports, FDA had already begun the process of reviewing available data to determine whether there is an increased risk of suicidal behavior in adults taking antidepressants. The Agency has asked manufacturers to provide information from their trials using an approach similar to that used in the evaluation of the risk of suicidal behavior in the pediatric population taking antidepressants. This effort will involve hundreds of clinical trials and may take more than a year to complete.

    [July 08, 2005 - Healthcare Professional and Patient Information Sheets - FDA]
    [June 30, 2005 - Public Health Advisory - FDA]
    [June 30, 2005 - Drug Information Page - FDA]

    Latest Cymbalta clinical trials